Pregnane X receptor as a therapeutic target to inhibit androgen activity

Endocrinology

Volumn 151, Issue 12, 2010, Pages 5721-5729

  Zhang, Bin ^a   Cheng, Qiuqiong ^a   Ou, Zhimin ^a,c   Lee, Jung Hoon ^a   Xu, Meishu ^a   Kochhar, Upasana ^a   Ren, Songrong ^a   Huang, Min ^c   Pflug, Beth R ^d   Xie, Wen ^a,b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c SUN YAT SEN UNIVERSITY   (China)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; CYTOCHROME P450 3A; HYDROXYSTEROID SULFOTRANSFERASE; PREGNANE X RECEPTOR; RIFAMPICIN;

ANIMAL EXPERIMENT; ARTICLE; CASTRATION; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME INACTIVATION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE; PROTEIN EXPRESSION;

ANIMALS; CELL LINE, TUMOR; CYTOCHROME P-450 ENZYME SYSTEM; GENE EXPRESSION; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; ORCHIECTOMY; PREGNENOLONE CARBONITRILE; PROSTATE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RECEPTORS, STEROID; REGENERATION; SULFOTRANSFERASES; TESTOSTERONE; TESTOSTERONE PROPIONATE;

EID: 78649891122     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2010-0708     Document Type: Article

References (31)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ 2008 Cancer statistics, 2008. CA Cancer J Clin 58:71-96
2. Huggins C 1943 Endocrine control of prostatic cancer. Science 97: 541-544
3. Tammela T 2004 Endocrine treatment of prostate cancer. J Steroid Biochem Mol Biol 92:287-295
4. Suzuki H, Kamiya N, Imamoto T, Kawamura K, Yano M, Takano M, Utsumi T, Naya Y, Ichikawa T 2008 Current topics and perspectives relating to hormone therapy for prostate cancer. Int J Clin Oncol 13:401-410
5. Bubley GJ 2001 Is the flare phenomenon clinically significant? Urology 58:5-9
6. Huirne JA, Lambalk CB 2001 Gonadotropin-releasing-hormone-receptor antagonists. Lancet 358:1793-1803
7. Denmeade SR, Isaacs JT 2002 A history of prostate cancer treatment. Nat Rev Cancer 2:389-396
8. Strott CA 2002 Sulfonation and molecular action. Endocr Rev 23: 703-732
9. Kauffman FC 2004 Sulfonation in pharmacology and toxicology. Drug Metab Rev 36:823-843
10. Chan J, Song CS, Matusik RJ, Chatterjee B, Roy AK 1998 Inhibition of androgen action by dehydroepiandrosterone sulfotransferase transfected in PC-3 prostate cancer cells. Chem Biol Interact 109: 267-278
11. Falany CN 1997 Enzymology of human cytosolic sulfotransferases. FASEB J 11:206-216
12. Dunn 2nd RT, Klaassen CD 1998 Tissue-specific expression of rat sulfotransferase messenger RNAs. Drug Metab Dispos 26:598-604
13. Song CS, Jung MH, Kim SC, Hassan T, Roy AK, Chatterjee B 1998 Tissue-specific and androgen-repressible regulation of the rat dehydroepiandrosterone sulfotransferase gene promoter. J Biol Chem 273:21856-21866
14. Keshava C, McCanlies EC, Weston A 2004 CYP3A4 polymorphisms - potential risk factors for breast and prostate cancer: a HuGE review. Am J Epidemiol 160:825-841
15. Blumberg B, Sabbagh Jr W, Juguilon H, Bolado Jr J, van Meter CM, Ong ES, Evans RM 1998 SXR, a novel steroid and xenobiotic-sensing nuclear receptor. Genes Dev 12:3195-3205
16. Kliewer SA, Moore JT, Wade L, Staudinger JL, Watson MA, Jones SA, McKee DD, Oliver BB, Willson TM, Zetterström RH, Perlmann T, Lehmann JM 1998 Anorphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell 92:73-82
17. Sonoda J, Xie W, Rosenfeld JM, Barwick JL, Guzelian PS, Evans RM 2002 Regulation of a xenobiotic sulfonation cascade by nuclear pregnane X receptor (PXR). Proc Natl Acad Sci USA 99:13801-13806
18. Down MJ, Arkle S, Mills JJ 2007 Regulation and induction of CYP3A11, CYP3A13 and CYP3A25 in C57BL/6J mouse liver. Arch Biochem Biophys 457:105-110
19. Gong H, Singh SV, Singh SP, Mu Y, Lee JH, Saini SP, Toma D, Ren S, Kagan VE, Day BW, Zimniak P, Xie W 2006 Orphan nuclear receptor pregnane X receptor sensitizes oxidative stress responses in transgenic mice and cancerous cells. Mol Endocrinol 20:279-290
20. Xie W, Barwick JL, Downes M, Blumberg B, Simon CM, Nelson MC, Neuschwander-Tetri BA, Brunt EM, Guzelian PS, Evans RM 2000 Humanized xenobiotic response in mice expressing nuclear receptor SXR. Nature 406:435-439
21. Lee JH, Gong H, Khadem S, Lu Y, Gao X, Li S, Zhang J, Xie W 2008 Androgen deprivation by activating the liver X receptor. Endocrinology 149:3778-3788
22. Ellwood-Yen K, Wongvipat J, Sawyers C 2006 Transgenic mouse model for rapid pharmacodynamic evaluation of antiandrogens. Cancer Res 66:10513-10516
23. Chen Y, Tang Y, Wang MT, Zeng S, Nie D 2007 Human pregnane X receptor and resistance to chemotherapy in prostate cancer. Cancer Res 67:10361-10367
24. Fang HL, Strom SC, Ellis E, Duanmu Z, Fu J, Duniec-Dmuchowski Z, Falany CN, Falany JL, Kocarek TA, Runge-Morris M 2007 Positive and negative regulation of human hepatic hydroxysteroid sulfotransferase (SULT2A1) gene transcription by rifampicin: roles of hepatocyte nuclear factor 4α and pregnane X receptor. J Pharmacol Exp Ther 323:586-598
25. Debes JD, Tindall DJ 2002 The role of androgens and the androgen receptor in prostate cancer. Cancer Lett 187:1-7
26. Heinlein CA, Chang C 2004 Androgen receptor in prostate cancer. Endocr Rev 25:276-308
27. Sharifi N, Gulley JL, Dahut WL 2005 Androgen deprivation therapy for prostate cancer. JAMA 294:238-244
28. Kroboth PD, Salek FS, Pittenger AL, Fabian TJ, Frye RF 1999 DHEA and DHEA-S: a review. J Clin Pharmacol 39:327-348
29. Wilborn TW, Lang NP, Smith M, Meleth S, Falany CN 2006 Association of SULT2A1 allelic variants with plasma adrenal androgens and prostate cancer in African American men. J Steroid Biochem Mol Biol 99:209-214
30. Guengerich FP 1999 Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 39:1-17
31. Uppal H, Saini SP, Moschetta A, Mu Y, Zhou J, Gong H, Zhai Y, Ren S, Michalopoulos GK, Mangelsdorf DJ, Xie W 2007 Activation of LXRs prevents bile acid toxicity and cholestasis in female mice. Hepatology 45:422-432